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The MET proto-oncogene, encoding the tyrosine kinase receptor for Hepatocyte Growth
Factor (HGF) regulates invasive growth, a genetic program that associates control of cell
proliferation with invasion of the extracellular matrix and protection from apoptosis. Phys-
iologically, invasive growth takes place during embryonic development, and, in post-natal
life, in wound healing and regeneration of several tissues. The MET oncogene is over-
expressed and/or genetically mutated in many tumors, thereby sustaining pathological
invasive growth, a prerequisite for metastasis. MET is the subject of intense research as a
target for small molecule kinase inhibitors and, together with its ligand HGF, for inhibitory
antibodies.The tight interplay of MET with the protease network has unveiled mechanisms
to be exploited to achieve effective inhibition of invasive growth.
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THE MET TYROSINE KINASE AND THE INVASIVE GROWTH
PROGRAM
The MET proto-oncogene encodes the tyrosine kinase receptor
for Hepatocyte Growth Factor (HGF), also known as Scatter Fac-
tor (SF; Giordano et al., 1989; Naldini et al., 1991). This ligand
is synthesized as an inert single-chain precursor, and then con-
verted into an active α- and β-chain heterodimer by extracellular
proteases, including members of the blood coagulation system,
such as urokinase-type plasminogen activator (uPA) and factor
XII. Interestingly, HGF itself shares a high degree of homology
with coagulation factors, as the α chain contains plasminogen-like
“kringle” structural motifs, and the β chain contains a domain
homologous to serine proteases, but devoid of enzymatic activity
by substitution of critical aminoacids in the catalytic site (Figure 1;
for a review see Trusolino and Comoglio, 2002).
The MET receptor is synthesized as a single-chain precursor
that undergoes post-translational cleavage into two disulfide-
linked α and β subunits. The extracellular domain contains two
main regions, both involved in ligand binding. The first is the
“sema domain,” named after its homology with the signaling mol-
ecules semaphorins, which includes the α chain and an N-terminal
portion of the β chain. The second is the “immunoglobulin-
like domain,” containing four disulfide-linked, loop structures
(Figure 1; Gherardi et al., 2003). The intracellular domain of
MET includes three functional portions with aminoacidic residues
critical for modulation of signaling properties: (i) a juxtamem-
brane sequence including Ser975, which, upon phosphorylation,
downregulates kinase activity; (ii) a catalytic region, containing
Tyr1234 and Tyr1235, which, upon receptor dimerization and
transphosphorylation, upregulate kinase activity; (iii) a carboxy-
terminal sequence including Tyr1349 and Tyr1356 that works as a
multifunctional docking site required and sufficient to recruit the
core of cytoplasmic signal transducers and adaptors (Figure 1; for
review see Trusolino and Comoglio, 2002; Trusolino et al., 2010).
Hepatocyte growth factor and MET control a complex bio-
logical program defined as “invasive growth” (Trusolino and
Comoglio, 2002). This program coordinates cell proliferation
with cell invasion, and provides protection from apoptosis usu-
ally occurring in cells removed from their physiological context.
MET-driven invasive growth is a physiological program taking
place during embryonic development and post-natal tissue growth
and regeneration (Birchmeier and Gherardi, 1998; Boccaccio and
Comoglio, 2006; Trusolino et al., 2010).
The signaling pathways that couple MET activation with the
invasive growth biological program are largely shared with other
growth factor receptors, and include in the first place MAP Kinase
and PI-3 Kinase-AKT pathways, but also STAT3, p38, and NF-kB
pathways. However, as compared with other growth factor recep-
tors, MAP kinase and PI-3 Kinase are usually activated by MET
with greater intensity and duration. The ability of MET to hyper-
activate PI-3 kinase and MAPK signaling is thought to be essential
for the pro-invasive activity. This hyperactivation results from
aggregation of a complex signaling platform that amplifies the bio-
chemical input, and translates it into specific biological outcomes.
This platform includes the intracellular docking protein Gab1, and
several cell surface proteins such as: (i) CD44v6, required to link
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FIGURE 1 | Schematic representation of the receptor tyrosine kinase
encoded by the MET oncogene, its ligand HGF, and the main
experimental drugs against the receptor or the ligand currently under
investigation (engineered MET/HGF antagonists, anti-HGF antibodies,
anti-Met antibodies, small-molecule Met inhibitors).The α and β chains of
both receptor and ligand are represented. In the receptor, the aminoacidic
residues undergoing phosphorylation during signal activation are also
indicated. For explanation of the specific domain functions, mechanisms of
ligand-receptor interaction, and mechanism of action of experimental drugs,
see text.
the MET cytoplasmic tail to the actin cytoskeleton and, together
with Gab1, to sustain activation of the MAP kinase cascade; (ii)
α6β4 integrin, acting as a supplementary docking platform for
amplification of PI-3 Kinase, MAP kinase, and SRC-dependent
pathways; (iii) B family plexins, the receptors for semaphorins,
which can trans-activate MET in the absence of HGF (for a review
see Trusolino et al., 2010).
THE MET ONCOGENE IN CANCER
Inappropriate activation of the MET oncogene has been reported
in a wide variety of human tumors, where it supports execution
of pathological invasive growth, leading to cancer aggressiveness
and metastatic dissemination (Comoglio et al., 2008). MET genetic
alterations are relatively rare, and include chromosomal rearrange-
ments, a panel of point mutations, and gene amplification. The
chromosomal rearrangement TPR-MET, observed in gastric can-
cers, results in the expression of a completely intracellular fusion
protein that comprises a constitutive dimerization motif and the
MET intracellular domain (Soman et al., 1991). Point mutations
of MET were found in both hereditary and sporadic papillary
renal cancer (Schmidt et al., 1997) and gastric carcinoma (Lee
et al., 2000), in childhood liver carcinoma (Park et al., 1999), and
lymph node metastases of head and neck squamous carcinoma
(Di Renzo et al., 2000). Interestingly, MET point mutations have
been recently associated with the so-called “cancers of unknown
primary origin” (CUP). These are highly undifferentiated tumors
that present at their very onset as metastatic dissemination in the
absence of a detectable primary tumor (Stella et al., 2011). MET
amplification, resulting in overexpression and constitutive kinase
activation, has been found in gastric and esophageal carcinomas
(Houldsworth et al., 1990), and medulloblastomas (Tong, 2004).
Of special interests is MET amplification emerging in non-small
cell lung carcinomas (NSCLC) treated with drugs targeting epi-
dermal growth factor receptor (EGFR; Bean et al., 2007; Engelman
et al., 2007). These results provided a rationale for combining
EGFR and MET inhibitors in lung cancer clinical trials.
The most frequent cause of constitutive MET activation in
human tumors is overexpression of a structurally normal protein,
which results from transcriptional upregulation. Indeed, MET
transcription can be sustained through mechanisms activated by
frequent cancer genetic alterations such as Ras mutation (Ivan
et al., 1997), p53 loss (Hwang et al., 2011), or MACC1 expression
(Stein et al., 2009). In addition, MET transcription is induced
by environmental cues, such as growth factors secreted by the
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adjacent stroma, including HGF itself, or by oxygen deficiency, or
hypoxia, a frequent occurrence in the rapidly growing tumor tissue
(Pennacchietti et al., 2003). Recently, we have shown that Met tran-
scriptional upregulation, mediated by transcription factor NF-kB,
and Met tyrosine kinase activation, leading to cell invasion and
protection from apoptosis, occur when cells are exposed to ioniz-
ing radiations. Conversely, the use of Met inhibitors sensitizes cells
to radiotherapy (De Bacco et al., 2011).
Finally, the discovery that MET protein translation is impaired
by miRNA (Migliore et al., 2008), has led to the observation that
loss of“tumor suppressor”miRNAs can cause MET overexpression
during colorectal cancer progression (Migliore et al., 2012).
STRATEGIES TO TARGET MET
MET inhibition has been pursued by trying to interfere with each
of the main steps controlling MET activation, namely: (i) MET
interaction with its ligand HGF; (ii) MET receptor oligomeriza-
tion; (iii) MET catalytic activity; (iv) MET downstream signaling
(for review see Comoglio et al., 2008; Gherardi et al., 2012). These
studies have led to formulation of compounds that fall in the
following three main classes.
ENGINEERED PROTEINS ANTAGONIZING HGF AND MET
The complex mechanism of interaction between HGF and MET
has been elucidated through structural and crystallographic stud-
ies. HGF includes two binding sites for MET: a high-affinity
binding site located in the α chain, which binds the MET
immunoglobulin-like domains (Basilico et al., 2008), and a low-
affinity binding site located in the β chain, which binds the MET
sema domain (Stamos et al., 2004; Figure 1). Isolated domains of
HGF or MET proteins have been shown to antagonize HGF-MET
binding and block the ensuing MET biological effects in preclinical
models. The best characterized antagonist is NK4, corresponding
to the HGF α chain, and named after the “four kringle” (K) struc-
tural motifs (Figure 1). Interestingly, it has been observed that NK4
has a bifunctional role, targeting both the tumor and the microen-
vironment, as it displays also a powerful anti-angiogenic effect (for
a review see Matsumoto and Nakamura, 2008). A similar effect has
been reported also for an engineered molecule called“decoy MET,”
corresponding to the isolated, soluble MET extracellular domain
(Michieli et al., 2004). The anti-angiogenic effect of HGF/Met
antagonists is explained by the ability of HGF to directly promote
endothelial cell growth as well as VEGF expression (for a review see
Gherardi et al., 2012). NK4, moreover, can exert an anti-angiogenic
effect by mimicking angiostatin (for a review see Matsumoto and
Nakamura, 2008). Finally, other engineered protein successfully
tested in experimental models as HGF/Met antagonists are: (i)
NK2, a naturally occurring splice variant of HGF, including the
first two kringle domains (Chan et al., 1991), and (ii) the isolated
Sema domain (see above; Kong-Beltran et al., 2004; Figure 1).
ANTIBODIES AGAINST HGF AND MET
A humanized monoclonal antibody that binds the HGF β chain
(rilotumumab, or AMG102, developed by Amgen; Figure 1), and
inhibits HGF binding to MET, has displayed excellent neutral-
izing activity in experimental models (Burgess et al., 2006), and
is currently tested in several Phase II clinical trials in recurrent
glioblastoma, kidney, and gastric carcinoma, and other tumors1.
Another humanized anti-HGF antibody, currently investigated in
Phase II clinical trials for NSCLC, is ficlatuzumab (developed by
AVEO; see text footnote 1).
The available antibodies against MET include DN30 (devel-
oped by Metheresis; Prat et al., 1998; Petrelli, 2006), and the
so-called “METMab” (onartuzumab, developed by Genentech and
Roche; Jin et al., 2008; Figure 1). DN30 is a monoclonal antibody
that eventually induces proteolytic cleavage and release of the MET
extracellular domain (see below). This process causes not only full
receptor inhibition, but also ligand neutralization, which results
from interaction of the solubilized MET extracellular domain with
HGF bound to the extracellular matrix (“decoy effect”). However,
on MET binding, DN30 retains a partial agonist activity that has
been circumvented by transforming the original IgG divalent form
into a monovalent form (Pacchiana, 2010). This antibody is in a
preclinical development stage. METMab is a humanized mono-
valent antibody with neutralizing activity against MET, which,
administered in association with EGFR inhibitors to patients
affected by NSCLC, has significantly increased the “progression-
free survival” period of patients that expressed high levels of MET
(Spigel, 2011).
SMALL MOLECULE MET INHIBITORS
MET catalytic activity can be blocked by small molecule inhibitors
that compete for ATP binding at the kinase active site. A group of
these compounds, sharing a common structure (an indolin-2-one
core), display specific activity against MET, and include, among
the most selective and potent, PHA665752 (Pfizer; Smolen, 2006),
EMD1214063, and EMD1204831 (Serono), and JNJ38877605
(Jhonson and Jhonson; De Bacco et al., 2011; Figure 1). These
molecules are still in a preclinical or early clinical developmen-
tal phase, and, in the case of JNJ38877605, have raised serious
concerns for possible human toxicity (for a review see Peters and
Adjei, 2012). Another small molecule MET inhibitor, Tivantinib
(also known as ARQ197, developed by Arqule), does not compete
for ATP binding to the MET catalytic site, and acts through alter-
native but still poorly characterized mechanisms (Eathiraj et al.,
2011; Figure 1). However, it is in advanced stage of clinical devel-
opment and, in combination with EGFR inhibitors, has shown
remarkable activity in extending the progression-free survival of
patients with NSCLC (Sequist et al., 2011).
Other inhibitors with broader specificity, concomitantly target-
ing the tyrosine kinase activity of MET and other receptors, are
currently tested in Phase II-III trials. Among the most investigated,
Crizotinib (also known as PF-02341066, developed by Pfizer)
inhibits MET, ALK, RON, AXL, and TIE2. In phase III trials, Crizo-
tinib has shown a striking activity in NSCLC patients harboring the
rare EML4-ALK translocation, leading to expression of a consti-
tutively active ALK kinase (Kwak et al., 2010). Cabozantinib (also
known as XL184, developed by Exelixis) inhibits MET, VEGFR2,
RET, KIT, FLT3, and TIE2. This compound showed significant
activity against a variety of primary and metastatic tumors, among
which the most remarkable are metastatic castration-resistant
1http://www.vai.org/metclinicaltrials/
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prostate cancer (Hussain, 2011), and medullary thyroid cancer
(Kurzrock et al., 2011). Obviously, in case of broad specificity
inhibitors, it is hard to discriminate the contribution of MET
inhibition to the overall therapeutical effect.
MET REGULATION BY PROTEASES AND ITS THERAPEUTIC
IMPLICATIONS
Over the past few years the existence of a cross-talk between
proteases and tyrosine kinases became increasingly evident
(Lopez-Otin and Hunter, 2010). Earlier studies described the
ability of MET to activate several proteases, such as Matrix-
metalloproteinase-9 (MMP-9; Harvey et al., 2000). The impor-
tance of the reverse regulation, i.e., modulation of MET (or other
receptor tyrosine kinases) by proteases, became apparent only
recently, but proved to be relevant for the development of new
cancer therapies (Schelter, 2010; Schelter et al., 2011).
One of the first findings indicating regulation of proteases
by MET was that co-expression of MET and HGF increased the
metastatic potential of NIH3T3 fibroblasts in vivo, by sustaining
constitutive activation of MET signaling and proteolytic activity
(Rong et al., 1994). As proteolytic activity is generally considered
a prerequisite for metastasis (Deryugina and Quigley, 2006; Fin-
gleton, 2006), several subsequent studies addressed the regulatory
effect of MET signaling on pro-invasive proteases. The observation
that pro-invasive MMP-9 can be induced by MET signaling (Har-
vey et al., 2000) is of special interest, as MMP-9, as well as its close
relative MMP-2, can cleave collagen type IV, the main component
of the basement membrane, a physiological boundary that only
fully malignant cells can trespass (Egeblad and Werb, 2002). Beside
activation of members of the matrix-metalloproteinase family, it
was also shown that MET signaling induces expression and activity
of other proteases, including urokinase-type plasminogen acti-
vator (uPA) (Jeffers et al., 1996). Taken together, these findings
significantly contributed to provide a mechanistic explanation for
the pro-invasive effect of HGF, or “invasive growth” (Trusolino
and Comoglio, 2002).
It is well known that termination of MET signaling is achieved
by down-regulation of this receptor, which occurs after induc-
tion of phosphorylation. The canonical process of MET down-
regulation mostly relies on endocytosis, and seems to be protease-
independent (for a review see Trusolino et al., 2010). However,
there are parallel mechanisms of down-regulation, which are
indeed protease-dependent. One mechanism was found in apop-
totic cells, where MET is cleaved by caspases, resulting in block-
age of MET-mediated survival signals (Foveau et al., 2007). This
process could be inactivated in cancer cells, which are often unable
to unleash the apoptotic pathway, leading to MET accumulation,
and further support of anti-apoptotic signals.
A second mechanism of protease-dependent MET down-
regulation involves extracellular proteases. We previously reported
that, in a murine model, elevated levels of systemic Tissue Inhibitor
of Metalloprotease-1 (TIMP-1) promoted metastatic dissemina-
tion of tumor cells to the liver. This effect was dependent on
increased activity of the MET signaling pathway in the liver tis-
sue microenvironment (Kopitz et al., 2007). This observation
suggested the hypothesis that the endogenous broad spectrum
inhibitor TIMP-1 inhibited a potential MET sheddase, causing
accumulation of MET on the cell surface, and hyperactivation of
MET signaling (Kopitz et al., 2007). Earlier reports (Nath et al.,
2001; Lee et al., 2002) had shown that, under physiological condi-
tions, MET shedding was mediated by a protease sensitive to tissue
inhibitor of metalloproteinases-3 (TIMP-3), thus likely belong-
ing to “A Disintegrin And Metalloproteinase (ADAM)” family,
which includes prominent mediators of cell surface protein shed-
ding (Murphy, 2008). In particular, it was known that TIMP-3
can inhibit ADAM-10 and ADAM-17, whereas TIMP-1 can only
inhibit ADAM-10 (Amour et al., 1998, 2000). In our attempt to
explain the pro-metastatic effect of TIMP-1, mediated by MET
accumulation, we obtained the first evidence that ADAM-10 is a
MET sheddase (Kopitz et al., 2007), a finding further confirmed by
other studies (Schirrmeister et al., 2009; Schelter, 2010; Doberstein
et al., 2011; Schelter et al., 2011). Moreover, also ADAM-17, a close
functional homolog of ADAM-10, was identified as a potential
MET sheddase (Foveau et al., 2009). Taken together, these find-
ings explain the early observation that MET shedding can rely on
TIMP-3-sensitive proteases, as both ADAM-10 and ADAM-17 are
inhibited by TIMP-3 (Amour et al., 1998, 2000). We concluded
that, in the liver microenvironment, elevated levels of TIMP-1
inhibited MET shedding in liver cells, leading to MET accumu-
lation and increased signaling, thereby providing a fertile soil for
colonization by metastatic cells (host effect; Kopitz et al., 2007).
Moreover, we showed that inhibition of MET shedding by TIMP-1
occurs also in cancer cells, thus sustaining their invasive growth
potential and ability to colonize the liver (Schelter et al., 2011).
Taken together, these studies show that regulation of MET sig-
naling by proteases is relevant in the context of cancer. Therefore,
the question arises whether this mechanism can be exploited to
develop anti-cancer therapies. Previously, it was shown that a
MET-specific monoclonal antibody (DN30) induces shedding of
MET and inhibition of MET signaling (Petrelli, 2006), strongly
suggesting the involvement of an ADAM protease in the anti-
body’s mechanism of action. Indeed we recently showed that
ADAM-10 (but not ADAM-17) mediated MET shedding induced
by DN30, and thus it was critical for the therapeutic effect of this
antibody (Schelter, 2010). Knockdown of ADAM-10, but not of
ADAM-17, abolished MET down-regulation in different tumor
cell lines, and compromised the DN30 ability to block MET sig-
naling (Schelter, 2010). Moreover, also the DN30 ability to inhibit
HGF-dependent tumor cell scattering and invasiveness in vitro
was shown to depend on ADAM-10 (Schelter, 2010). These find-
ings led to the conclusion that patients should be screened for
ADAM-10 expression before being treated with DN30, as ADAM-
10 is required for the activity of this antibody. Furthermore, these
observations suggest the possibility to finely tune the specificity of
targeted therapies, such as the DN30 antibody, by combining the
activity of the antibody and the protease required for its activity.
CONCLUSION
The tyrosine kinase receptor encoded by the MET oncogene is
expressed in a wide variety of tumors, where it often displays a
deregulated activity that leads to pathological “invasive growth,”
featuring invasion, and metastasis. Moreover, MET is expressed
by endothelial cells, and can be involved in tumor angiogene-
sis. The connection between MET and tumor microenvironment
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs September 2012 | Volume 3 | Article 164 | 4
Luraghi et al. MET in cancer invasive growth
is emphasized by the interplay with matrix proteases, such as
ADAM-10, that modulate its activity. Overall, MET hyperactiva-
tion is likely to play a crucial role in tumor onset and progression.
MET and its ligand HGF are attractive pharmacological targets:
the ligand and the receptor extracellular domain can be blocked
by antibodies, or by engineered protein antagonists, while the tyro-
sine kinase activity can be inhibited by small molecules. Antibodies
and kinase inhibitors are currently tested in clinical trials with
encouraging results.
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